2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $60M | -$114M | 40.5% | -177.8% | -$101M | $41M | $238M |
| 2024 | $28M | -$94M | 1.3% | -305.8% | -$84M | $43M | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Jan '26 | $25M | -$34M | 52.6% | -141.6% | — | $42M | $291M |
| Oct '25 | $23M | -$33M | 50.6% | -140.7% | -$26M | $42M | $175M |
| Jul '25 | $19M | -$26M | 45.7% | -149.1% | -$34M | $41M | $201M |
| Jan '25 | $15M | -$22M | 43.4% | -136.5% | — | — | $54M |
| Oct '24 | $15M | -$20M | 39.6% | -130.1% | -$23M | — | $77M |
| Jul '24 | $13M | -$20M | 32.9% | -144.2% | -$25M | — | $100M |
How the market has priced KMTS against its own fundamentals since 2025-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 1 years, KESTRA MEDICAL TECHNOLOGIES, LTD.'s revenue has grown 115.1% per year. These are computed facts, not advice.
As of FY2025, KESTRA MEDICAL TECHNOLOGIES, LTD. reported $41M of total debt against $238M of cash; operating income covered interest expense -13.8×.
In FY2025, gross margin was 40.5%, operating margin -177.8%, and net margin -190.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.